Table 1

Details of the nine positive thrombectomy trials

TrialTrial datesCentresParticipantsPrimary outcome measureAge (years)Onset of symptomsNIHSS
MR CLEAN352010–1416502mRS at 90 days≥18≤4.5≤6>1
REVASCAT36*2012–144206mRS at 90 days18–80‡≤4.5≤8>5
EXTEND 1A372012–141070Reperfusion at 24 hours,
NIHSS at day 3
≥18≤4.5≤6No restriction
SWIFT-prime382012–1439196mRS at 90 days18–80≤3.5≤68–29
ESCAPE392013–1422316mRS at 90 days≥18≤4.5≤12>5
THRACE402010–1526402mRS≤2 at 90 days18–80≤4≤510–25
THERAPY41*2012–1436108mRS≤2 at 90 days18–85≤4.5§≤8¶>7
PISTE422013–151065mRS≤2 at 90 days≥18≤4.56No restriction
EASI43*2013–14177mRS≤2 at 3 months≥18<3≤6>7**
  • *Enrolment was halted early after positive results for thrombectomy were reported from other similar trials.

  • †Trial stopped early due to efficacy.

  • ‡After enrolling 160 patients, inclusion criteria were modified to include patients up to the age of 85 years with an ASPECTS >8.

  • §Three-hour limit if patient>80 with diabetes, previous stroke, previous anticoagulation and NIHSS>25.

  • ¶Revised protocol reduced cut-off to 5 hours.

  • **Or the presence of clinical imaging mismatch, and suspected or proven occlusion of the M1 or M2 segments of the middle cerebral artery, supraclinoid internal carotid artery or basilar artery.

  • IV r-tPA, intravenous thrombolysis with recombinant tissue-type plasminogen activator; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale.